Article Text

Download PDFPDF
Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies
  1. J A G Lown,
  2. A S Hughes,
  3. P Cannell
  1. Department of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia
  1. Correspondence to:
    Mr John A G Lown
    Transfusion Medicine Unit, Royal Perth Hospital, GPO Box X2213, Perth, WA 6847, Australia;


Patients receiving abciximab occasionally develop transient severe thrombocytopenia within a few hours of receiving the drug. Thrombocytopenia has been reported to resolve within 10 days of abciximab administration, but in this case profound thrombocytopenia lasted 21 days before a slow spontaneous recovery. Management was complicated by the presence of HLA antibodies and the transient production of antibodies directed at major platelet glycoproteins IIb/IIIa, Ib/IX, and Ia/IIa. The patient remained refractory to platelet transfusion and two courses of intravenous gammaglobulin for the duration of her admission.

  • abciximab
  • platelet antibodies
  • thrombocytopenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Linked Articles